INDP Profile
Indaptus Therapeutics, Inc. is an innovative clinical biotechnology firm specializing in the development of advanced immunotherapy treatments targeting cancer and viral infections. The company is at the forefront of creating novel therapeutic products aimed at addressing complex medical conditions through its cutting-edge research and clinical programs. One of Indaptus Therapeutics' most promising assets is its lead clinical candidate, Decoy20. This therapeutic agent is designed to elicit durable responses either as a standalone treatment or in combination with other therapies for various malignancies, including lymphoma, hepatocellular carcinoma, colorectal cancer, and pancreatic tumors. Additionally, Decoy20 is being evaluated for its efficacy in treating chronic hepatitis B virus (HBV) and human immunodeficiency virus (HIV) infections.
Decoy20 is currently in Phase I clinical trials, where it is being tested for safety, tolerability, and preliminary efficacy. The ongoing trials are critical for determining the potential of Decoy20 to provide long-lasting therapeutic benefits and to establish its role in the broader treatment landscape for oncology and virology. The development of this product underscores Indaptus Therapeutics' commitment to advancing next-generation immunotherapies that can offer new hope to patients with difficult-to-treat conditions.
Previously known as Intec Parent, Inc., the company rebranded to Indaptus Therapeutics, Inc. in August 2021, reflecting its strategic focus on immunotherapy and its evolving research pipeline. Headquartered in New York, New York, Indaptus Therapeutics is positioned in one of the world’s leading biotechnology hubs, allowing it to leverage a rich ecosystem of scientific expertise, investment opportunities, and industry partnerships.
Indaptus Therapeutics is dedicated to expanding its research capabilities and advancing its clinical programs. The company is actively working to build a diverse portfolio of immunotherapy solutions, and it places significant emphasis on innovation and collaboration. By focusing on unmet medical needs and pursuing novel therapeutic approaches, Indaptus Therapeutics aims to make a meaningful impact in the fields of oncology and virology, ultimately improving patient outcomes and contributing to the advancement of medical science.
|
